Clinical Trial Update: PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of PF-06952229 in adults with advanced solid tumors was terminated. Results were posted on 2024-06-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Liver Cancer
• Melanoma
• Mesothelioma
• Pancreatic Cancer
• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• PF-06952229 (PF-06952229)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms, Prostate Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2024-06-26